Prediction of response to infliximab in Crohn's disease

Digestive and Liver Disease

Volumn 37, Issue 8, 2005, Pages 559-563

  Chaudhary, R ^a   Ghosh, S ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; FC RECEPTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BILE DUCT CARCINOMA; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG INFUSION; EUROPE; GENETIC POLYMORPHISM; HUMAN; INTESTINE FISTULA; INTESTINE RESECTION; ITALY; LEUKEMIA; MEDICAL DECISION MAKING; METHODOLOGY; PATIENT CARE; PHARMACOGENOMICS; PREDICTION; REMISSION; RHEUMATOID ARTHRITIS; SURGICAL DRAINAGE; TREATMENT FAILURE; TREATMENT OUTCOME; AGE; DRUG COMBINATION; GENETICS; NOTE; RECTUM FISTULA; SMOKING;

AGE FACTORS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; RECTAL FISTULA; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644617999     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.04.002     Document Type: Note

References (22)

1. Orlando A., Mocciaro F., Colombo E., Kohn A., Biancone L., Rizzello F., et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 37 (2005) 577-583
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al., ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
3. Parsi M.A., Achkar J.P., Richardson S., Katz J., Hammel J.P., Lashner B.A., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 (2002) 707-713
4. Arnott I.D., McNeill G., and Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 15 (2003) 1451-1457
5. Parsi M.A., Lashner B.A., Achkar J.P., Connor J.T., and Brzezinski A. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol 99 (2004) 445-449
6. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
7. Vermeire S., et al., Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 97 (2002) 2357-2363
8. Kinney T., Rawlins M., Kozarek R., France R., and Patterson D. Immunomodulators and 'on demand' therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 98 (2003) 608-612
9. Ghosh S. Maintenance therapy versus episodic therapy with infliximab for Crohn's disease. Nat Clin Practice Gastroenterol Hepatol 1 (2004) 81
10. Weinberg A.M., Rattan S., Lewis J.D., Su C., Katzka D.A., Deren J., et al. Strictures and response to infliximab in Crohn's disease. Am J Gastroenterol 97 (2002) S255
11. Lionetti P., Bronzini F., Salvestrini C., Bascietto C., Canani R.B., De Angelis G.L., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 18 (2003) 425-431
12. Buch M.H., Seto Y., Bingham S.J., Bejarano V., Bryer D., White J., et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 52 (2005) 42-48
13. Mugnier B., Balandraud N., Darque A., Roudier C., Roudier J., and Reviron D. Polymorphism at position -308 of the tumour necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48 (2003) 1849-1852
14. Louis E., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Pescatore P., et al. A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37 (2002) 818-824
15. Mascheretti S., Hampe J., Croucher P.J., Nikolaus S., Andus T., Schubert S., et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 12 (2002) 509-515
16. Vermeire S., Louis E., Rutgeerts P., De Vos M., Van Gossum A., Belaiche J., et al., Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123 (2002) 106-111
17. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
18. Louis E., El Ghoul Z., Vermeire S., Dall'Ozzo S., Rutgeerts P., Paintaud G., et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 19 (2004) 511-519
19. Esters N., Vermeire S., Joossens S., Noman M., Louis E., Belaiche J., et al., Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 97 (2002) 1458-1462
20. Taylor K.D., Plevy S.E., Yang H., Landers C.J., Barry M.J., Rotter J.I., et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120 (2001) 1347-1355
21. Mascheretti S., Hampe J., Kuhbacher T., Herfarth H., Krawczak M., Folsch U.R., et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2 (2002) 127-136
22. Pierik M., Vermeire S., Steen K.V., Joossens S., Claessens G., Vlietinck R., et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 20 (2004) 303-310